Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization.
about
Protein kinase C signaling and cell cycle regulationThe retinoblastoma family proteins bind to and activate diacylglycerol kinase zetaActivation of PKC-delta and SHP-1 by hyperglycemia causes vascular cell apoptosis and diabetic retinopathyEmerging role of protein kinase C in energy homeostasis: A brief overviewOxidative Stress-Related Mechanisms and Antioxidant Therapy in Diabetic RetinopathyDiabetic macular edema: New promising therapies.Expression of protein kinases C betaI, betaII, and VEGF during the differentiation of enamel epithelium in tooth development.Molecular mechanisms of diabetic vascular complicationsDiabetic macular edema: new concepts in patho-physiology and treatment.Activation of protein kinase C isoforms and its impact on diabetic complications.Diabetic macular edema: new trends in management.Antiproliferative activity of PEP005, a novel ingenol angelate that modulates PKC functions, alone and in combination with cytotoxic agents in human colon cancer cells.Responding to hypoxia: lessons from a model cell line.A small molecule disruptor of Rb/Raf-1 interaction inhibits cell proliferation, angiogenesis, and growth of human tumor xenografts in nude mice.Protein kinase C inhibition and diabetic retinopathy: a shot in the dark at translational researchGrowth factors and protein kinase C inhibitors as novel therapies for the medical management diabetic retinopathy.Vascular endothelial growth factor induces MEF2C and MEF2-dependent activity in endothelial cells.Protein kinase cβ phosphorylates occludin regulating tight junction trafficking in vascular endothelial growth factor-induced permeability in vivo.Glomerular VEGF resistance induced by PKCδ/SHP-1 activation and contribution to diabetic nephropathy.Absolute quantitation of isoforms of post-translationally modified proteins in transgenic organism.Protein kinase C β inhibition by enzastaurin leads to mitotic missegregation and preferential cytotoxicity toward colorectal cancer cells with chromosomal instability (CIN)Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.The protein kinase C-beta inhibitor, ruboxistaurin, for the treatment of diabetic microvascular complications.Hypericin inhibits pathological retinal neovascularization in a mouse model of oxygen-induced retinopathy.PTEN encoding product: a marker for tumorigenesis and progression of gastric carcinoma.Vascular complications of diabetes: mechanisms of injury and protective factorsClinical safety of the selective PKC-beta inhibitor, ruboxistaurin.Emerging drugs for age-related macular degeneration.Protein kinase C beta inhibition: A novel therapeutic strategy for diabetic microangiopathy.Using the past to inform the future: anti-VEGF therapy as a road map to develop novel therapies for diabetic retinopathyStrategies for blocking angiogenesis in diabetic retinopathy: from basic science to clinical practice.RB1, development, and cancer.The therapeutic role of targeting protein kinase C in solid and hematologic malignancies.A pharmacokinetic and safety study of a fixed oral dose of enzastaurin HCl in native Chinese patients with refractory solid tumors and lymphoma.Current and future approaches in the prevention and treatment of diabetic retinopathy.Selective disruption of rb-raf-1 kinase interaction inhibits pancreatic adenocarcinoma growth irrespective of gemcitabine sensitivity.Protein kinase C Beta in the tumor microenvironment promotes mammary tumorigenesis.Novel agents for diffuse large B-cell lymphoma.Is there a world beyond bevacizumab in targeting angiogenesis in glioblastoma?Novel therapies, including enzastaurin, in the treatment of ovarian cancer.
P2860
Q21131217-CE7C758B-AFC5-4BF5-8753-22B4D313B4C0Q24294841-D0A89010-6C78-4038-AC4E-C432E0D9C5D7Q24628949-3D7C7FC1-1748-447A-BEA9-08D890EE86B4Q27022044-82A8D1AE-35D4-4EE2-B68D-A7BAB409B4E1Q29248994-2CD9245F-44A9-4D0B-BC0A-1323D99FA558Q30415630-8E9D1AED-6CB7-4696-B073-0C9CCDF7C7DAQ31148906-6A7EBEF4-2668-4F31-B097-84FCCDEDAE4EQ33558421-F95FE5A1-973D-4F09-9714-7ACB5C28736AQ33713517-8BDA5019-955A-45C7-88FD-FC87008E6DA9Q33881442-1AE8C1DA-D7B0-4B7B-8668-323EDDA27994Q34091784-D2D7B801-53DE-4727-8608-6D2410D6B893Q34600909-BB21C1F3-3F86-4D1D-8B69-A8ACD6C64674Q34790987-4577AABB-BD56-40D0-BB80-F904976335CCQ35601503-6318FDA7-E020-4AB3-81E2-656AFC2CC348Q35615435-4B80D094-787D-4EC6-92EF-AA7A378551A3Q35648554-2282D67F-5EA8-4913-B7BE-7CA1D5BEB875Q35900356-21082F20-61FE-4C2B-83D9-CE38F63858E8Q35976653-C84A17F8-4084-4698-BD93-23F9872B90BCQ36055520-04F3ECB6-D078-461F-BD51-AB11D658EF2CQ36144125-965866B4-4BF4-4E8A-939C-136C0208B6E3Q36187549-2DDEF0B1-9A2E-465B-94ED-04C99D351FE8Q36256287-0A0A5CA9-7459-4215-A487-BF946E9814C1Q36322082-4EB0942B-ADFD-4037-BBF6-76877F5EDE0FQ36479091-1C54A4F2-2B17-4831-9FC6-0EF9CCF96792Q36506366-1378901A-3C30-4CE1-B216-042EAE026C7DQ36537262-A39F1FF3-C1ED-43ED-A9A1-4A3A1748A7CEQ36624994-F09A4C1B-A361-4C0C-B36C-9B0AEB1C085DQ36634283-6BA5F992-A7BD-4BC3-A32B-434B3028C95EQ36679604-6FDB6E81-A0FB-437A-9814-950A2EC95200Q36867626-C5D543CD-68B7-4401-9D81-AC7D72157501Q36904857-21896255-0FED-45FA-BF17-0FD149F5982AQ36950978-B6B57A67-66A4-485B-94D7-9A674B7B3715Q36964732-839B9197-784A-4BAD-A25C-DEE7856004B5Q37109823-17C51FC9-0614-4360-A65D-A823B12CF279Q37221516-9DB5D61A-593C-445A-8AEA-80672209463EQ37381557-E76EAD26-D367-424A-8E75-A6F7A85BC98CQ37735031-E65CB429-A4D6-4BC3-B312-E7352880FF94Q37858532-48F28189-238E-4EC9-899B-FE93BBE32980Q37993124-1BC53AB4-483D-41E3-9B9B-D2CED2BC960CQ38198095-B481F435-41BB-47F9-93F9-6A955E498D07
P2860
Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization.
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Characterization of protein ki ...... and retinal neovascularization
@nl
Characterization of protein ki ...... nd retinal neovascularization.
@ast
Characterization of protein ki ...... nd retinal neovascularization.
@en
type
label
Characterization of protein ki ...... and retinal neovascularization
@nl
Characterization of protein ki ...... nd retinal neovascularization.
@ast
Characterization of protein ki ...... nd retinal neovascularization.
@en
prefLabel
Characterization of protein ki ...... and retinal neovascularization
@nl
Characterization of protein ki ...... nd retinal neovascularization.
@ast
Characterization of protein ki ...... nd retinal neovascularization.
@en
P2093
P2860
P921
P356
P1476
Characterization of protein ki ...... nd retinal neovascularization.
@en
P2093
George L King
Izumi Suzuma
Keiji Isshiki
Kiyoshi Suzuma
Lloyd Paul Aiello
Michael Leitges
Noriko Takahara
P2860
P304
P356
10.1073/PNAS.022644499
P407
P50
P577
2002-01-01T00:00:00Z